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ABSTRACT
Objective: Colon cancer is a major public health problem. Soybean has demonstrated chemopreventive and anticancer. Here, we have investigated 
the effect of a standardized seed and soybean meal extract (SE) with content of lunasin, here named grobogan extract (GE) and SE. They are botanical 
drug substance in experimental models of colon cancer in vivo.
Methods: The effect of GE and SE was examined on the preneoplastic lesions (aberrant crypt foci), polyps and tumors induced by the carcinogenic 
agent azoxymethane (10 mg/kg) and dextran sodium sulfate 2% as well as in a xenograft model of colon cancer in mice.
Results: GE and SE increased apoptosis (p=0.001). GE (150 mg/kg) has the highest impact level of apoptosis (p=0.009). GE and SE decreased dysplasia 
(p=0.024). GE (200 mg/kg) has the highest impact level of dysplasia (p=0.002), and SE (200 mg/kg) has the second impact level of dysplasia (p=0.003).
Conclusions: GE and SE inhibition of colon carcinogenesis with increased level of apoptosis and decrease level of dysplasia.
Keywords: Soybean, Lunasin, Colon cancer, Azoxymethane, Dextran sodium sulfate, Apoptosis, Dysplasia.
INTRODUCTION
Colorectal cancer (CRC) represents the third most common cancer 
in men (746,000 cases, 10% of the total) and the second in women 
(614,00 cases, 9.1% of the total) worldwide [1]. Almost 55% CRC occur 
in more developed country but it is inevitable this time the incidence 
of CRC increased in developing country. It is happened because of 
change in diet and lifestyle, among other: Increased consumption of red 
meat and processed foods, decreased consumption of foods containing 
fiber (fruits and vegetables), increased weight (obesity), low physical 
activity, smoking and high alcohol intake [1,2].
Pharmacoeconomic studies have highlighted a trend for rising cost 
associated with CRC, which is linked to the increasing use of targeted 
biological therapies [3]. Screening strategies are utilized but have not 
reduced disease incidence or mortality [4]. Furthermore, therapeutic 
intervention, which is by itself very toxic, may fail to prevent disease 
progression to metastatic disease [5]. Therefore, there is an interest in 
both cancer preventive strategies - which include experimentation with 
safe phytochemical agents - and new curative treatments [6].
Soybean (Glycine max) is an ancient legume consumed worldwide, but 
most commonly in Asian countries, such as China, Japan, Korea, Taiwan, 
and Indonesia. The demographic consumption pattern of soybean 
varies geographically with Asians utilizing (20-80 g/day), mostly in 
the forms of traditional soy foods and fermented soy foods, such as 
soybean, soy milk, tofu, tempeh, misso, natto, soybean paste, and soy 
sauce [7,8] as compared to Western population consuming meagerly 
(1-3 g/day), mostly in processed forms, such as soy drinks, breakfast 
cereals, energy bar and soy burger [9].
Epidemiological evidence has demonstrated an association between 
the consumption of soybean and improved health, particularly as a 
reduced risk for cardiovascular diseases [10] and cancer, such as breast, 
prostate, endometrial, lung, and bladder cancer [11-17]. Moreover, a 
number of animal models support anticancer properties of soy which 
constituents have been shown to suppress tumor growth in a variety 
of tissues including skin, bladder, mammary, and prostate [18]. In last 
decades, studies have isolated and identified an array of biologically 
active compounds or phytochemicals contained in soybean with cancer 
preventive effects.
A likely candidate is lunasin, a novel cancer preventive peptide, the 
efficacy of which has been demonstrated in our laboratory [19-22]. 
Initially identified in soy, lunasin is also present in barley, a food crop 
known for its health effects [21]. Lunasin is a unique 43 amino acid 
soybean peptide that contains at its carboxyl end 9 Asp (D) residues, 
an Arg-Gly-Asp (RGD) cell adhesion motif, and a predicted helix with 
structural homology to a conserved region of chromatin-binding 
proteins. It has been shown to suppress carcinogenesis caused by 
chemical carcinogens and oncogenes in in vitro models and a mouse 
model for skin cancer [19-22].
Histone acetylation and deacetylation have been associated with 
eukaryotic transcriptional regulatory mechanisms [23]. The affinity 
of lunasin for hypoacetylated chromatin suggests a role in chromatin 
modification, a process implicated in cell cycle control and in the 
role of tumor suppressors in carcinogenesis [24]. Transfection of the 
lunasin gene into mammalian cells leads to mitotic arrest and cell 
lysis, resulting in lunasin bound to the chromatin [25]. Subsequently, 
we showed that exogenous addition of synthetic lunasin peptide to 
mammalian cells inhibits histone acetylation in the presence of sodium 
butyrate, a histone deacetylase inhibitor [22]. Because lunasin inhibits 
core H3 and H4 histone acetylationin mammalian cells [22], we propose 
an epigenetic mechanism whereby lunasin selectively kills cells that 
are being transformed or newly transformed cells by disrupting the 
dynamics of histone acetylation-deacetylation, which is triggered by 
the inactivation of tumor suppressors that operate through histone 
acetylation deacetylation [19].
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i4.16276
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In this paper, we used the inhibition of carcinogenesis by lunasin as 
a bioactivity assay for the first time. These were measured in lunasin 
extracted from a number of Indonesian soybean varieties and soybean 
meal through oral administration to measure apoptosis and dysplasia.
METHODS
Plant material and extranction
Soybean is obtained from Indonesian Legumes and Tuber Crops 
Research Institute Malang of East Java, Indonesia. Soybean varieties 
were used in this study is Grobogan because its content highest protein 
than other varieties (to reach 43.9%). Soybean meal is obtained from 
local market in Semarang of Central Java, Indonesia.
Before extraction, samples of soybean Grobogan pressed, to separate 
oil. The residue obtained from pressing process is made of powder 
with blender. The procedures for maceration were in accordance 
with previous studies [26,27]. The residue of grobogan seed and 
soybean meal are macerated with phosphate buffer saline solvent (1:5, 
60 minutes) and filtrated twice. Filtrate of grobogan and soybean meal 
be dried with rotary vapor and kept temperature below 60°C. The result 
was tested by high performance liquid chromatography to determine 
the content of lunasin.
Animal
Male Swiss-Webster mice (12 weeks old) of ±20 g body weight, supplied 
by Agency for Health Research and Development Ministry of Health of 
the Republic of Indonesia. The mice were maintained under standard 
laboratory conditions housed in independent ventilation cages (with 
stainless steel grill top, 48 cm × 35 cm × 20 cm) under hygienic and 
under controlled humidity conditions (55%±5%), light (12 hrs/12 hrs 
light/dark cycle), and temperature (23±1°C). The mice were allowed 
free access to food and water. The animals were carefully examined 
for 1 week prior to use in the experiments, and only healthy animals 
were chosen. All protocols and surgical procedures were approved by 
the Institute of Animal Care and Use Committees of Medical Faculty 
University of Indonesia.
Induction of colon cancer
Induction of colon carcinogenesis adopted Kusmardi et al.: Mice 
induced with azoxymethane (AOM) were dissolved in 0.9% NaCl at a 
dose of 10 mg/kg body weight by intraperitoneal (i.p.) injection early as 
one. 1 week after induction of AOM, mice given standard feed and water 
containing dextran sodium sulfate (DSS) 2% daily for 1 week [28].
Experimental groups
Mice were randomized into nine experimental groups as follows: Normal 
group, mice oral administration of physiological saline for 4 weeks, 
without a single i.p. injection AOM and DSS; negative group, mice oral 
administration of physiological saline for 4 weeks, and received a single 
i.p. injection AOM and DSS; positive group, mice oral administration 
of aspirin (150 mg/kg) for 4 weeks, and received a single i.p. injection 
AOM and DSS; grobogan treatment group, mice oral administration of 
grobogan extract (GE) (75, 150, 200 mg/kg, respectively) for 4 weeks, 
and received a single i.p. injection AOM and DSS; soybean meal 
treatment group, mice oral administration of soybean meal extract (SE) 
(75, 150, 200 mg/kg, respectively) for 4 weeks, and received a single 
i.p. injection AOM and DSS. After 4 weeks treatment, mice of each group 
were sacrificed to know inhibition of colon carcinogenesis.
Hematoxylin eosin staining
A piece of colorectal tissue made paraffin blocks. Paraffin blocks made 
4 μm thick slices and mounted on glass objects for HE staining stages 
as follows: Deparaffinizesection using xylol I, II and III, respectively 
5 minutes. Then re-hydrated using absolute alcohol, 96% and 70% 
respectively for 5 minutes, and washed in running water for 5 minutes. 
The preparation inserted into hematoxylin (Meyer solution) for 
7 minutes and rinsed in running water for 10 minutes. After that, the 
stocks dipped into a saturated lithium carbonate 1-2 minutes and 
rinsed with running water for 5 minutes.
Preparations controlled if the blue color is sufficient, if it is not put 
back into solution Meyer (hematoxylin) for 2 minutes, then rinsed in 
running water, soaked in eosin for 1-2 minutes, dehydrated in alcohol 
absolute 70%, 80%, 96% respectively for 3 minutes, clearing with xylol 
I - II - III, and the last drops with entelan and covered with a glass lid.
Preparations viewed using a light microscope with ×400 magnification. 
Histological assessment was done in a blinded fashion to avoid bias. 
Based on H&E staining, histological alterations, such as mucosal 
ulceration, dysplasia, and carcinoma, were verified by a board-certified 
pathologist. Carcinoma was defined as a high-grade dysplasia of the 
colonic mucosa that had invaded beyond the muscularis mucosa and 
into the submucosa.
Immunohistochemistry
For cleaved-caspase 3 immuno-histochemistry analysis, colorectal 
tissue deriving from mice were fixed in buffered formalin, embedded 
in paraffin, and cut into 4 μm-thick serial sections. Sections were 
stained with the cleaved-caspase 3 (1:100 v/v) antibodies. After three 
5-minute washes, the secondary antibody was added and the samples 
were incubated at room temperature for 20 min. The streptavidin-
HRP detection system was added and samples were incubated at 
room temperature. After three 5-minute washes, 50 ml of chromogen 
was added and the reaction stopped after 1 min in water. Histological 
analysis colorectal tissues were fixed in 10% formalin. Thin (0.5 mm) 
paraffined section were prepared and stained with toluidine blue as 
and then processed for light microscopy with ×400 magnification.
Statistical analysis
All data are presented in mean±standard deviation. Differences in levels 
among treatment groups were analyzed by ANOVA using SPSS 20.0 
statistical package. A p<0.05 was considered significant statistically.
RESULTS
Weight body index group of mice with GE and SE is displayed in Table 1.
In grobogan group shows GE (150 mg/kg) has the highest weight body 
index, compared with other weight body index in grobogan treatment 
group. Weight body index of GE (150 mg/kg) has higer than weight 
body index of aspirin (control positive). In soybean meal group shows 
SE (150 mg/kg) has the highest weight body index, compared with 
other weight body index in soybean meal treatment group. Weight body 
index of SE (150 mg/kg) has higer than weight body index of aspirin 
(control positive).
DISCUSSION
Effect of giving seed and SE for weight body index as shown in Table 1. 
This Table 1 shows that weight body index of mice in all of the group 
treatment at weekly is above 1, which means that seed and SE contribute 
to weight gain in mice.
Soybean seeds contain to 40% of crude protein and about 20% of fat, 
and soybean meal characterized higher content of crude protein about 
Table 1: Weight body index group of mice with GE and SE
Group Weeks
1 2 3 4 5 6
Normal 1.11 1.18 1.20 1.18 1.17 1.23
Negative 1.12 1.23 1.25 1.28 1.30 1.41
Positive (aspirin) 1.13 1.21 1.24 1.22 1.18 1.23
GE (75 mg/kg) 1.08 1.19 1.19 1.21 1.20 1.21
GE (150 mg/kg) 1.10 1.21 1.24 1.28 1.27 1.32
GE (200 mg/kg) 1.09 1.17 1.26 1.19 1.16 1.22
SE (75 mg/kg) 1.09 1.18 1.20 1.21 1.19 1.20
SE (150 mg/kg) 1.08 1.19 1.18 1.21 1.19 1.25
SE (200 mg/kg) 1.04 1.08 1.07 1.05 1.05 1.08
GE: Grobogan extract, SE: Soybean meal extract
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40-49%. Protein of soybean products characterized much quantity 
of arginine, cystine, histidine, isoleucin, leucine, lysine, methionine, 
phenylalanine, theonine, tryptophan and valine [29].
Soybean contains isoflavones. These compounds have got biochemical 
activity, including treatment of chronic diseases. Studies in humans 
and animals have shown that the consumption of soybean or soybean-
derived products may help to protect against cardiovascular diseases, 
certain types of cancer, obesity, and diabetes [30]. The ability of 
isoflavones to prevent these diseases depends on their absorption, 
metabolism, distribution to target tissues and excretion of waste 
compounds, that is, their bioavailability. In other study showed that 
a diet containing soy isoflavones increased the body weight and fat 
percentage, also the serum concentrations of insulin-like growth 
factor-I (IGF-I) and interleukin-6 were increased by high levels of soy 
isoflavones [31].
Our results indicate that seed and SE provide protection against colon 
carcinogenesis in male AOM-induced Swiss Webster mice, specifically 
against earlier stages of colon carcinogenesis. This is evidenced by the 
higher incidence of apoptosis (Figs. 3 and 5) and the lower incidence 
of dysplasia (Figs. 4 and 6). In Fig. 3, with ANOVA analysis shows that 
GE and SE increased apoptosis (p=0.001). GE (150 mg/kg) has the 
highest impact level of apoptosis (p=0.009). In Fig. 5, it shows that 
immunohistochemistry to active caspase-3 for apoptosis detection. This 
figure shows that GE (150 mg/kg) has a same impact level of apoptosis 
with control positive. In this research, we use aspirin for control 
positive. Long-term aspirin use reduces the risk of colon cancer [32]. 
Mechanisms of aspirin for chemoprevention include inhibition of the 
cyclooxygenase (COX) pathway, or COX-independent mechanisms, for 
example, the PIK3CA pathway, or therapy-induced senescence of cancer 
cells [33].
In other study, it shows that the combination of etoricoxib and atorvastin 
against DMH-induced colon cancer by increasing the level of antioxidant 
enzymes. The histopathological this study demonstrated that the 
combination treatment showed more positive effect in the prevention 
of colon carcinogenesis by reducing the inflammation, hyperplastic, 
dysplastic change in colon crypt cells [34]. Etoricoxib specifically 
binds to and inhibits the enzyme COX-2, resulting in inhibition of 
the conversion of arachidonic acid into prostaglandins. Inhibition of 
COX-2 may induce apoptosis and inhibit tumor cell proliferation and 
angiogenesis [35]. In this study used aspirin, it has same mechanism 
with etoricoxib. Aspirin exhibit increase level of apoptosis and decrease 
level of dysplasia in colon crypt cell (Figs. 3 and 4). Apoptosis and 
dysplasia are indication of carcinogenesis of colon cancer. In this study, 
adopt colitis-associated colon cancer. AOM and DSS can make chronic 
inflammatory process may contribute to multistep colon carcinogenesis 
in the inflamated colon. They include overproduction of reactive oxygen 
and nitrogen species, overproduction and upregulation of productions 
and enzymes of arachidonic acid biosynthesis pathway and cytokines, 
and intestinal immune system dysfunction [36]. Aspirin’s most well-
characterized pharmacologic activity is the permanent modification 
of the prostaglandin endoperoxide synthetase or COX enzymes. 
These enzymes are rate limiting for the conversion of arachidonic 
acid to prostaglandins and related eicosanoids. COX-1 isoenzyme is 
constitutively expressed in most tissues, whereas growth factors, 
oncogenes, tumor promoters, and inflammatory cytokines induce the 
COX-2 isoenzyme [37]. Treatment with aspirin for colitis-associated 
Fig. 2: Experimental protocol for colon carcinogenesis model. 
Normal (without induced AOM and DSS), Negative (induced AOM 
and DSS without intervention), Positive (control  with aspirin), GE 
: Grobogan extract,  SE: Soybean Meal extract.
Fig. 3: Mean score apoptosis of mice with grobogan extract and 
soybean meal extract (p=0,001). *p<0.05 compared to control 
negative group, **p<0.01 compared to control negative group
Fig. 4: Mean score dysplasia of mice with grobogan extract and 
soybean meal extract (p=0,024), *p<0.05 compared to control 
negative group, **p<0.01 compared to control negative group
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colon cancer in this study assumed that inhibiting inflammatory 
process can prevent colon carcinogenesis.
Soybeans are known a low-risk food for cancer, and correlation 
between the intake of soybean foods and the morbidity of cancer 
[38]. Dietary agents known used natural inhibitors of insulin-like 
growth factor-1 receptor (IGF-1R) for the management of tumors. 
IGF-1R is a member of the receptor tyrosine kinase superfamily the 
ligand binding leads to receptor activation and phosphorylation of 
downstream substrates. Signaling through IGF-1R in normal cells 
leads to the activation of multiple intracellular pathways, mediated by 
the receptor associated tyrosine kinase domain, PI-3 kinase, and by 
serine/threonine kinase (Akt), yielding growth and enhanced survival. 
In cancer cells, IGF-1R plays an even more critical role because it 
contributes to the promotion of tumor growth by inhibition of the 
apoptosis, transformation, metastasis, and induction of angiogenesis 
through the vascular endothelial growth factor [39]. Soybean down-
regulated a set of genes that are necessary for the angiogenesis 
pathway in LNCaP, PC-3, and DU-145 PCa cells. These genes included 
platelet-derived endothelial cell growth factor 1, fibroblast growth 
factor 1 (FGF1), IGF1, FGF receptor 3 (FGFR3), interlukin-1β (IL-1β), 
IL-6, IL-8, platelet/endothelial cell adhesion molecule (CD31 antigen 
or PECAM1), CXCL10, and many other molecules that are essential to 
angiogenesis [40]. That study shown that soybean can prevent colon 
carcinogenesis by inhibition of IGF-1R.
Lunasin in soybean acts as a surrogate tumor suppressor that tightly 
binds to deacetylated core histones disrupting the balance between 
acetylation-deacetylation, which is perceived by the cell as abnormal 
and leads to cell death [41]. This first mechanism of action involving 
histone acetylation inhibition is considered as one of the most 
important epigenetic modifications acting on signal transduction 
pathways involved in cancer development [42,43]. When the cells 
are in the steady-state conditions, the core H3 and H4 histones are 
mostly deacetylated, as a repressed state. When cells were treated 
with peptide lunasin and well-known deacetylase inhibitor sodium 
butyrate, histone acetylation was inhibited in C3H10T1/2 fibroblasts 
and breast cancer MCF-7 cells [44-46]. Furthermore, lunasin has been 
demonstrated to compete with different histone acetyltransferase 
enzymes (HATs), such as yGCN5 and PCAF, inhibiting the acetylation 
and repressing the cell cycle progression [46-49]. Recently, we have 
reported that lunasin is a potent inhibitor of histones H3 and H4 histone 
acetylation [49,50]. Lunasin’s inhibitory activity was found to be higher 
than that demonstrated by other compounds, such as anacardic acid 
and curcumin, which chemopreventive properties have been already 
reported [51-53]. Studies focused on elucidating lunasin’s structure-
activity relationship establish that lunasin’s sequence is essential for 
inhibiting H4 acetylation whereas poly-D sequence is the main active 
sequence responsible for H3 acetylation inhibition [50].
Lunasin has been demonstrated that it causes cytotoxicity in four 
different human colon cancer cell lines, KM12L4, RKO, HCT-116, and 
HT-29 cell, with IC50 values of 13.0 µM, 21.6 µM, 26.3 µM and 61.7 µM, 
respectively [54]. These values suggest that lunasin is most potent 
killing the highly metastatic KM12L4 colon cancer cells than any other 
colon cell lines used in this study. Moreover, lunasin was capable to 
provoke cytotoxic effects on the oxaliplatin-resistant variants of this 
colon cancer cells [55]. Studies on mechanism of action of this peptide 
have revealed that lunasin causes arrest of cell cycle in G2/M phase 
and induction of the mitochondrial pathway of apoptosis. The cell cycle 
arrest was attributed with concomitant increase in the expression of 
the p21 protein in HT-29 colon cancer cells, while both p21 and p27 
protein expressions were up-regulated by lunasin treatment in KM12L4 
colon cancer cells [54,56]. Moreover, treatment with lunasin decreased 
the ratio of Bcl-2: Bax by up-regulating the expression of the pro-
apoptotic Bax and downregulating the expression of the anti-apoptotic 
Bcl-2, also increasing the activity of caspase-3 [55]. This might be 
attributed to the increase in the expression of the pro-apoptotic form 
of clusterin which is positively affected by the increase p21 expression 
in cell nucleus. Treatment of lunasin causes translocation of Bax into 
the mitochondrial membrane resulting in the release of cytochrome 
c and the increase of the expression of cytosolic cytochrome c in 
KM12L4 cells. It was also demonstrated that treatment with lunasin 
provokes an increase in the activity of caspase-9 and caspase-3 in both 
HT-29 and KM12L4 cells [56]. Furthermore, lunasin has been showed 
to modify the expression of human extracellular matrix and adhesion 
genes [56]. The Arg-Gly-Asp motif present in the lunasin structure is 
a recognition site for integrin receptors present in the extracellular 
matrix (ECM). Integrins are heterodimeric receptors associated with 
cell adhesion, and cancer metastasis [57]. Treatment of KM12L4 cells 
with lunasin resulted in the modification on the expression of 62 
genes associated with ECM and cell adhesion [56]. These authors also 
reported that lunasin downregulated the gene expression of collagen 
type VII a1, integrin b2, matrix metalloproteinase 10, selectin E and 
integrin a5 by 10.1-, 8.2-, 7.7-, 6.5- and 5.0-fold, respectively, compared 
to the untreated CRC cells. On the other hand, the expression of collagen 
Fig. 5: Grobogan extract (GE) and soybean meal extract (SE) 
increase expression of caspase3. Relative amounts of caspase3 
were quantified using the Image J software. The values 
are expressed as the mean±SD, p<0,05; (a) Normal group, 
(b) negative group, (c) positive group, (d) GE 75 mg/kg), (e) GE 
150 mg/kg, (f) GE 200 mg/kg, (g) SE 75 mg/kg, (h) SE 150 mg/kg, 










Fig. 6: Grobogan extract (GE) and soybean meal extract (SE) 
decrease dysplasia. Relative amounts of dysplasia were 
quantified using the Image J software. The values are expressed 
as the mean±standard deviation, p<0.05; (a) normal group, 
(b) negative group, (c) positive group, (d) GE 75 mg/kg, (e) GE 
150 mg/kg, (f) GE 200 mg/kg, (g) SE 75 mg/kg, (h) SE 150 mg/kg, 
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type XIV a1 was up-regulated on lunasin treatment by 11.6-fold. These 
results suggest a potential role of peptide lunasin as an agent to combat 
metastatic colon cancer particularly in cases where resistance to 
chemotherapy develops.
In another study, colon cancer liver metastasis is a widely used model to 
study the effects of different markers and chemotherapy on colon cancer 
metastasis. Recently, Dia and Gonzalez de Mejia have reported that 
lunasin acts as chemopreventive agent against this type of metastasis 
using colon cancer KM12L4 cells directly injected into the spleen of 
athymic mice [54]. Lunasin administered at concentration of 4 mg/kg 
body weight resulted in a significant inhibition of liver metastasis of 
colon cancer cells, potentially because of its binding to a5b1 integrin 
and subsequent suppression of FAK/ERK/NF-kB signaling. Lunasin 
was also capable to potentiate the effect of oxaliplatin in preventing 
the outgrowth of metastasis. Moreover, lunasin potentiated the effect 
of oxaliplatin in modifying expression of proteins involved in apoptosis 
and metastasis including Bax, Bcl-2, IKK-a and p-p65 [50]. These results 
suggest that lunasin can be used as a potential integrin antagonist 
thereby preventing the attachment and extravasation of colon cancer 
cells leading to its anti-metastatic effect. These results open a new vision 
about the lunasin used in metastasis that might benefit to prolong the 
survival of mice with metastatic colon cancer [58].
Effect of giving seed and SE for dysplasia index as shown in Figs. 4 and 6. 
In Fig. 4 with ANOVA analysis shows that GE and SE decreased dysplasia 
(p=0.024). GE (200 mg/kg) has the highest impact level of dysplasia 
(p=0.002) and SE (200 mg/kg) has the second impact level of dysplasia 
(p=0.003). In Fig. 6, it shows that hematoxylin-eosin staining with 
dysplasia.
In another study, the effect of dietary supplementation with 
isoflavone - free soy protein concentrate (SPC) on colon inflammation and 
carcinogenesis in male, CF-1 mice was investigated in one 10-week and 
one 20-week study. In both studies, following one-week pretreatment 
with SPC or casein as the sole source of protein (19% kcal), mice were 
injected with the colon carcinogen (AOM, 10 mg/kg body wt). One 
week later, mice received (DSS, 1.5% w/v) as their sole drinking fluid 
for one week to induce colon-specific inflammation. On days 3 and 7, 
and weeks 7 and 20 (second study only) after DSS treatment, mice were 
euthanized and the colons were examined for markers of inflammation 
and carcinogenesis. All samples were scored using the inflammation 
index, which measures inflammation area, severity, ulceration and 
hyperplasia and dysplasia. In both studies, trends in these measures 
appeared to be highly dependent on sacrifice time-point. With the data 
from both studies combined, mean polyp multiplicity was significantly 
reduced in mice fed SPC at week 7 and for the study overall (p<0.001 
and p<0.01, respectively). Hyperplasia and dysplasia, inflammation 
area and total inflammation index score were significantly decreased in 
the SPC group compared to the control at week 7 (p<0.10, p<0.10 and 
p<0.05, respectively). At 20 weeks, mice in both the control and SPC-
treated groups showed colon tumors. The trend toward reduced tumor 
burden and multiplicity in mice fed the SPC diet was observed, but the 
effect was not statistically significant [59].
CONCLUSION
In conclusion, we have shown that GE and SE have beneficial actions in 
an experimental model of colon cancer. Both of them inhibition of colon 
carcinogenesis with increased level of apoptosis and decrease level of 
dysplasia.
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